Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10366228" target="_blank" >RIV/00216208:11110/17:10366228 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10366228

Výsledek na webu

<a href="http://dx.doi.org/10.1038/leu.2017.121" target="_blank" >http://dx.doi.org/10.1038/leu.2017.121</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2017.121" target="_blank" >10.1038/leu.2017.121</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004

Popis výsledku v původním jazyce

We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Munster (BFM) 04 protocol to determine the prognostic value of specific chromosomal aberrations including monosomal (MK+), complex (CK+) and hypodiploid (HK+) karyotypes, individually and in combination. Multivariate regression analysis identified in particular MK+ (n = 22) as a new independent risk factor for poor event-free survival (EFS 23 +/- 9% vs 53 +/- 2% for all other patients, P = 0.0003), even after exclusion of four patients with monosomy 7 (EFS 28 +/- 11%, P = 0.0081). CK+ patients without MK had a better prognosis (n = 47, EFS 47 +/- 8%, P = 0.46) than those with MK+ (n = 12, EFS 25 +/- 13%, P = 0.024). HK+ (n = 37, EFS 44 +/- 8% for total cohort, P = 0.3) influenced outcome only when t(8; 21) patients were excluded (remaining n = 16, EFS 9 +/- 8%, P &lt; 0.0001). An extremely poor outcome was observed for MK+/HK+ patients (n = 10, EFS 10 +/- 10%, P &lt; 0.0001). Finally, isolated trisomy 8 was also associated with low EFS (n = 16, EFS 25 +/- 11%, P = 0.0091). In conclusion, monosomal karyotype is a strong and independent predictor for high-risk pediatric AML. In addition, isolated trisomy 8 and hypodiploidy without t(8; 21) coincide with dismal outcome. These results have important implications for risk stratification and should be further validated in independent pediatric cohorts.

Název v anglickém jazyce

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004

Popis výsledku anglicky

We conducted a cytogenetic analysis of 642 children with de novo acute myeloid leukemia (AML) treated on the AML-Berlin-Frankfurt-Munster (BFM) 04 protocol to determine the prognostic value of specific chromosomal aberrations including monosomal (MK+), complex (CK+) and hypodiploid (HK+) karyotypes, individually and in combination. Multivariate regression analysis identified in particular MK+ (n = 22) as a new independent risk factor for poor event-free survival (EFS 23 +/- 9% vs 53 +/- 2% for all other patients, P = 0.0003), even after exclusion of four patients with monosomy 7 (EFS 28 +/- 11%, P = 0.0081). CK+ patients without MK had a better prognosis (n = 47, EFS 47 +/- 8%, P = 0.46) than those with MK+ (n = 12, EFS 25 +/- 13%, P = 0.024). HK+ (n = 37, EFS 44 +/- 8% for total cohort, P = 0.3) influenced outcome only when t(8; 21) patients were excluded (remaining n = 16, EFS 9 +/- 8%, P &lt; 0.0001). An extremely poor outcome was observed for MK+/HK+ patients (n = 10, EFS 10 +/- 10%, P &lt; 0.0001). Finally, isolated trisomy 8 was also associated with low EFS (n = 16, EFS 25 +/- 11%, P = 0.0091). In conclusion, monosomal karyotype is a strong and independent predictor for high-risk pediatric AML. In addition, isolated trisomy 8 and hypodiploidy without t(8; 21) coincide with dismal outcome. These results have important implications for risk stratification and should be further validated in independent pediatric cohorts.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

31

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

2807-2814

Kód UT WoS článku

000417177100032

EID výsledku v databázi Scopus

2-s2.0-85038233250